Journal of Isfahan Medical School

Journal of Isfahan Medical School

Trinucleotide Repeat Polymorphism in Transforming Growth Factor Beta Receptor Type 1 Gene and Risk of Breast Cancer

Document Type : Original Article (s)

Authors
Elahe Kamali 1
Manoochehr Tavassoli 2
Simin Hematti 3
Padideh Karimi 1
Parisa Kheradmand 1
1 MSc Student, Department of Biology, School of Science, University of Isfahan, Isfahan, Iran
2 Associate Professor, Department of Biology, School of Science, University of Isfahan, Isfahan, Iran
3 Assistant Professor, Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: Transforming growth factor beta receptor type 1 (TGFBR1) is a serine–threonine protein kinase which mediates the growth-inhibitory signals of TGFB1 through a complex with TGFBR2. Numerous epidemiological studies have evaluated the association of TGFBR1 polymorphisms and the risk of cancer. The purpose of this study was to investigate the tri-nucleotide polymorphism (GCG) in exon 1 of TGFBR1 gene and its association with risk of breast cancer in women.Methods: This study was conducted on 200 women with breast cancer and 200 healthy women in Isfahan, Iran. After DNA extraction from peripheral blood samples, desired sequence was amplified by polymerase chain reaction (PCR). Finally, GCG repeat polymorphism was determined by polyacrylamide gel electrophoresis and direct sequencing.Findings: The TGFBR1 gene allele distribution in studied women varied between 6 and 9. The most common allele in both controls and cases was (GCG)9. The frequencies of (GCG)6 allele or homozygote of (GCG)6 in patients were significantly lower than controls.Conclusion: Contrary to previous reports, our findings demonstrate that women who carry (GCG)6 allele of TGFBR1 gene are at lower risk of developing breast cancer. Our results suggest a protective role of this allele against breast cancer. 
Keywords
Polymorphism
Breast Cancer
Transforming growth factor beta receptor type 1
GCG repeat
  1. Dumitrescu RG, Cotarla I. Understanding breast cancer risk -- where do we stand in 2005? J Cell Mol Med 2005; 9(1): 208-21.
  2. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002; 2: 37.
  3. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2009; 20(3): 556-63.
  4. Harirchi I, Ebrahimi M, Zamani N, Jarvandi S, Montazeri A. Breast cancer in Iran: a review of 903 case records. Public Health 2000; 114(2): 143-5.
  5. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004; 4(11): 850-60.
  6. Rahman N, Stratton MR. The genetics of breast cancer susceptibility. Annu Rev Genet 1998; 32: 95-121.
  7. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, Sulem P, Kristjansson K, Arnason S, et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med 2004; 1(3): e65.
  8. Baxter SW, Choong DY, Eccles DM, Campbell IG. Transforming growth factor beta receptor 1 polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2002; 11(2): 211-4.
  9. Gordon KJ, Blobe GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta 2008; 1782(4): 197-228.
  10. Reiss M, Barcellos-Hoff MH. Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat 1997; 45(1): 81-95.
  11. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29(2): 117-29.
  12. Walker RA. Transforming growth factor beta and its receptors: their role in breast cancer. Histopathology 2000; 36(2): 178-80.
  13. Wang YQ, Qi XW, Wang F, Jiang J, Guo QN. Association between TGFBR1 polymorphisms and cancer risk: a meta-analysis of 35 case-control studies. PLoS One 2012; 7(8): e42899.
  14. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16(3): 1215.
  15. Pasche B, Kaklamani V, Hou N, Young T, Rademaker A, Peterlongo P, et al. TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. J Clin Oncol 2004; 22(4): 756-8.
  16. Jin Q, Hemminki K, Grzybowska E, Klaes R, Soderberg M, Zientek H, et al. Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer 2004; 112(1): 94-9.
  17. Feigelson HS, Patel AV, Diver WR, Stevens VL, Thun MJ, Calle EE. Transforming growth factor beta receptor type I and transforming growth factor beta1 polymorphisms are not associated with postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 15(6): 1236-7.
  18. Colleran G, McInerney N, Rowan A, Barclay E, Jones AM, Curran C, et al. The TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer. Breast Cancer Res Treat 2010; 119(2): 437-42.
  19. Jami MS, Hemati S, Salehi Z, Tavassoli M. Association between the length of a CA dinucleotide repeat in the EGFR and risk of breast cancer. Cancer Invest 2008; 26(4): 434-7.
  20. Javadi M, Hematti S, Tavassoli M. Polymorphic CA repeat length in insulin-like growth factor 1 and risk of breast cancer in Iranian women. Med Oncol 2012; 29(2): 516-20.
  21. Hu YS, Pan Y, Li WH, Zhang Y, Li J, Ma BA. Association between TGFBR1*6A and osteosarcoma: a Chinese case-control study. BMC Cancer 2010; 10: 169.
Journal of Isfahan Medical School
Volume 31, Issue 250 - Serial Number 250
July and August 2013
Pages 1369-1377

  • Receive Date 12 September 2013
  • Accept Date 06 April 2022